adebrelimab + nab-paclitaxel + oxaliplatin + tegafur + gimeracil + oteracil

This is a combination therapy consisting of adebrelimab (a PD-L1 inhibitor), nab-paclitaxel, oxaliplatin, and S-1 (tegafur, gimeracil, and oteracil). While the individual components and some chemotherapy combinations (like nab-paclitaxel + S-1, oxaliplatin + S-1, and nab-paclitaxel + oxaliplatin + S-1) are mentioned in the search results, this specific combination including adebrelimab is not directly discussed. It represents a combination of immunotherapy and chemotherapy agents, a strategy being explored for various cancers, but specific details regarding this exact four-drug (including S-1 as a single entity for the purpose of combination naming) combination are not available from the provided search context.